Plan your day: afternoon sessions at the Angiogenesis, Exudation, and Degeneration 2024 Conference

News
Article

The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting

A woman at a computer plans her day by looking at the calendar app. Image credit: ©andreaobzerova – stock.adobe.com

The afternoon sessions promise to be engaging and informative in this virtual conference. Image credit: ©andreaobzerova – stock.adobe.com

The the 21st annual Angiogenesis, Exudation, and Degeneration conference falls on Saturday, 3 February, 2024. The following talks are scheduled for the afternoon sessions of the Angiogenesis conference.

12:30 pm: Visual Function Testing and Complement Inhibition for the Treatment of GA

  • Comparability of Functional Retinal Testing Across Devices in AMD Patients and Normal Controls;
  • Functional Endpoints in Geographic Atrophy: An Analysis from the Chroma and Spectri Clinical Trials;
  • The Use of High Density Focal Photopic Microperimetry to Follow Response to Anti-Complement Therapy in Patients with Geographic Atrophy;
  • AI in GA: How to Screen, Identify and Monitor Patients in the Real-World; 2-year Expanded Efficacy Data from the GATHER 2 Trial;
  • Safety Findings from the GATHER Programme Including 2-year Results from the GATHER2 Trial;
  • Functional Consequences of Avacincaptad Treatment in the GATHER Trials;
  • Hypertransmission Defects and Ellipsoid Zone Integrity Dynamics in the GATHER Clinical Trials;
  • Does Initial GA Growth Rate Predict GA Lesion Growth Rate and Response to Therapy at 2 years: 2-year Follow-up Data from GATHER 2;
  • Update on Clinical Studies with Pegcetacoplan; Functional Benefits with Pegcetacoplan;
  • An Anchored-Matching Adjusted Indirect Comparison of the Phase 3 Trials for GA: Pegcatacoplan vs. Avacincaptad Pegol

2:30 pm: Real World Experience with Complement Inhibition for GA

  • Management of Geographic Atrophy with Pegcetacoplan in Clinical Practice: First Time Data Presentation from a Large Multi-Center Study;
  • Defining Occlusive Retinal Vasculitis; Retinal Vasculitis Following Intravitreal Pegcetacoplan: An Update from the ASRS ReST Committee.

3:00 pm: A panel discussion: Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD

3:30 pm: Emerging Therapies for Exudative AMD

  • KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study;
  • Clinical Trails Evaluating LX102 Anti-VEGF Gene Therapy in Patients with Wet AMD;
  • Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase 2 Pharmacodynamic Study;
  • First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD;
  • Sustained Release Vorolanib in Durasert E for Maintenance Therapy in wet AMD: First-Time Data from a Prospective, Controlled Phase 2 Trial of EYP-1901 – The DAVIO 2 Trial;
  • Subgroup Analysis of DAVIO 2 Results; Home OCT Guided Management of Patients with nAMD;
  • Longitudinal AI-based Fluid Quantification and its Implication for Remote Patient Monitoring;
  • Is 12 Weeks the New Norm? What Determines Why Some Patients Need More Frequent Intravitreal Dosing?

5:00 pm: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: High-Dose Aflibercept

  • 96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study;
  • Aflibercept 8mg for PCV Subgroup in the PULSAR Study;
  • Aflibercept 8mg for Diabetic Macular Oedema: Update on the 96-Week Results of the PHOTON Study;
  • Aflibercept 8 mg: Safety Outcomes from the CANDELA, PULSAR, and PHOTON Studies.

5:50 pm: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: Faricimab

  • Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME;
  • Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME;
  • Long Term Data (week 72) from the B-RVO and C-RVO Phase 3 Faricimab Programme
  • Voyager Study- Update on Faricimab in the Real World; Insights from Clinical Practice - Review of First Year Experience with Faricimab in the Real World.

6:50 pm: Diabetic Retinopathy and Retinal Vascular Diseases

  • OCT Angiography in Diabetic Retinopathy; Predictors of Diabetic Retinopathy Worsening on Ultrawide Field Imaging;
  • OCS-01 for Diabetic Macular Oedema: A New Perspective on Dexamethasone; Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: Interim Results from the First In-Human Phase 2 RIPPLE-1 Trial;
  • Subgroup analysis and effect of disease severity in the BEHOLD phase 2 study of UBX1325 in DM;
  • RZ402: A Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Oedema;
  • Oral 3TC for Center-Involved Diabetic Macular Oedema: A Randomized Clinical Trial;
  • APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as the Endpoint;
  • The Path Forward for PDS: Technical Data Supporting Device Improvements and Septum Dislodgement Mitigation;
  • The impact of Continuous Delivery of Ranibizumab with PDS on Retinal Nonperfusion in Diabetic Retinal Disease;
  • Combined Analysis of BUTTERFLEYE/FIREFLEYE NEXT Aflibercept for ROP Treatment Trials and the Emerging ROP Prevention Trials;
  • What’s New with MacTel2?
Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.